Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?

Executive Summary

Steroid treatment like Emflaza is considered standard of care and availability of other products may make payer discussions difficult.


Related Content

Patient-Centered Promotion? Marathon's Non-Launch Of Emflaza Illustrates Challenge Of New Era
Marathon's High-Priced Window May Not Stay Open Long
Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch
Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108
Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates
Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review
Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy
Priority Review Politics: With Two Pending DMD Products, FDA Still Faces Community Anxiety
Priority Review Vouchers Appear To Be Dropping In Price
KV’s Suit Against FDA Is Revived By Thiopental Ruling, Compounding Law


Related Companies